Combating immunity to AAVEnsuring as many patients as possible can benefit from gene therapy
The Duchenne Research Fund has awarded a grant to Dr Barry Byrne and Dr Manuela Corti’s team at the University of Florida, whose vital work focuses on overcoming immunological challenges to ensure all boys and young men can benefit from gene therapy treatments for Duchenne muscular dystrophy.
Why is this research needed?
It is extremely positive news for the Duchenne community that there are currently several gene therapy treatments in clinical trial to combat Duchenne. However, around a third of young people already have a pre-existing immunity to the virus that is used to deliver the gene therapy treatment (known as an adeno-associated virus, or AAV). This means that those patients are unable to participate in current gene therapy trials.
In addition, patients who are eligible to receive the gene therapy will develop immunity to the virus after receiving the first dose, so the challenge of immunity must be overcome in order for them to receive any future doses.
What are the aims of the project?
Dr Byrne and Dr Corti’s work involves developing a strategy to allow dosing in cases of pre-immunity, by modifying the immune system. They aim to establish at what threshhold pre-immunity impacts the safety and efficacy of AAV administration, and to develop a protocol to reduce anti-AAV titers in pre-immune individuals with Duchenne.
They believe this work will have a major impact on the application of gene therapy approaches and provide valuable insight into safe and effective AAV-mediated gene therapy for Duchenne muscular dystrophy.
Dr Barry Byrne is the Associate Chair of Pediatrics and Director of the Powell Center for Rare Disease Research and Therapy. Click here to learn more about his work.
Funded in 2019-20
Latest research news
We have awarded £40,000 to the newly launched DMD Care UK, partnering with the project’s founders Duchenne UK and Joining Jack. Together our three charities will invest £130,000 in the nationwide initiative that aims to ensure the best care for everyone living with Duchenne in the UK …
ReveraGen BioPharma has received a $3.3 million grant from the NIH – the US National Institutes of Health – for their work on Vamorolone …
Ultragenyx Pharmaceutical and Solid Biosciences have announced a strategic collaborations and license agreement to focus on the development and commercialisation of new gene therapies for Duchenne …
Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne…
Solid Biosciences has issued an update on IGNITE DMD, the Phase I/II clinical study with its microdystrophin gene therapy, SGT-001.
We are so proud that the family of our founders, Kerry and Doron Rosenfeld, starred in Paul O’Grady’s Little Heroes on ITV …
The devastating impact of steroids
Click here to learn more about the effects that current steroid treatments have on boys with Duchenne.